One example of the use of DARPins for immuno‐oncology purposes is that of MP0250, a drug candidate that binds and inhibits vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), thus altering the tumor microenvironment (Baird et al., 2021). This evidence concerns the gene VEGFA and neoplasm.